Business
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemiaMENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medi
About this update from Berry Genomics Co. Ltd. Class A
[{"type":"image","alt":"PacBio","displaySize":"","headline":null,"caption":"PacBio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/ca3b97d5b827c8cc2602900e245a01c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nO_Xed3UYAG.Z8cezVsIzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca3b97d5b827c8cc2602900e245a01c9","width":300,"height":263}},"lazy":false},{"type":"text","content":"NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia","length":170,"tagName":"p"},{"type":"text","content":"MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical Products Administration (NMPA) in China.","length":378,"tagName":"p"},{"type":"text","content":"This marks the world’s first regulatory clearance of a clinical-grade long-read sequencer, a milestone led by Berry Genomics that signals a new era for precision medicine and high-accuracy genomic testing in China.","length":214,"tagName":"p"},{"type":"text","content":"High-incidence genetic disorders such as thalassemia often involve complex variant types that are difficult or impossible to detect using short-read sequencing.","length":160,"tagName":"p"},{"type":"text","content":"With the Sequel II CNDx system, clinicians can now access a complete picture of the genome in a single test—capturing single nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs), structural variants (SVs), and repeat expansions with exceptional accuracy.","length":292,"tagName":"p"},{"type":"text","content":"When paired with Berry’s newly approved clinical thalassemia assay and software system, this approval delivers the first end-to-end long-read sequencing workflow for China’s hospitals and diagnostic laboratories, optimized for carrier, prenatal, newborn, and rare disease testing.","length":280,"tagName":"p"},{"type":"text","content":"“PacBio’s mission is to enable the p...